Recently, we have shown that treatment of rat C6 glioma cells for 30 min with the lipid rafts disruptor methyl-β-cyclodextrin (MCD) doubles the binding efficiency (i.e., the maximum binding:affinity constant ratio) of CB1R, and thus the CB1R-dependent actions of endocannabinoids; instead, MDC did not affect those activities mediated by CB2R or TRPV1 (Bari et al., 2005). This evidence concerns the gene CNR1 and central nervous system cancer.